Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (DE:H5P)
FRANKFURT:H5P
H5P Stock Chart & Stats
€17.90
€0.00(0.00%)
At close: 4:00 PM EST
€17.90
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€17.20 - €28.40
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
€4.00B
Enterprise Value€6.06B
Total Cash (Recent Filing)€236.00M
Total Debt (Recent Filing)€1.55B
Price to Earnings (P/E)11.9
Beta0.49
Next Earnings
Feb 26, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.03
Shares Outstanding221,886,460
10 Day Avg. Volume0
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.41
Price to Sales (P/S)1.78
P/FCF Ratio13.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.01Price Target Upside50.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Investment OpportunityA market overreaction has created an opportunity for investors, as recent macro tariff news has inappropriately affected Hikma, exposing both short- and long-term opportunity.
Market DemandStrong demand in European and MENA markets, while North America benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio.
Strategic PositioningHikma is well positioned with market tariff concerns due to a strong US manufacturing presence and limited import exposure.
Bears Say
Revenue Growth ChallengesCompany continues to expect 7-9% FY25 revenue growth, with phasing and mix of sales expected to impact margins in 1H, but FY25 core operating margin maintained in the mid-30s.
Hikma Pharmaceuticals News
H5P FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest stock price was €17.20 and its highest was €28.40 in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Hikma Pharmaceuticals PLC’s market cap is €4.00B.
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Aug 07, 2025. The company reported €1.03 earnings per share for the quarter, beating the consensus estimate of €0.95 by €0.08.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC does not currently pay dividends.
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate is 0.91.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of €1.03 in its last earnings report, beating expectations of €0.95. Following the earnings report the stock price went down -5.557%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in DE:H5P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€27.01 (50.90% Upside)
€27.01 (50.90% Upside)
Blogger Sentiment
Bullish
DE:H5P Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth £1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.58%
12-Months-Change
Fundamentals
Return on Equity
15.66%
Trailing 12-Months
Asset Growth
5.70%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
H5P Stock 12 Month Forecast
Average Price Target
€27.01
▲(50.90% Upside)
Technical Analysis
Allergy Therapeutics
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―
Options Prices
Currently, No data available
---